Immunosyn Execs Hit With $20M Insider Trading Suit

Law360, New York (August 2, 2011, 5:13 PM EDT) -- Executives at San Diego biotechnology firm Immunosyn Corp. hyped an experimental HIV drug, raising $20 million from investors, then sold their shares without disclosing that the drug's approval process was on hold, regulators claimed Monday in an Illinois insider trading suit.

The U.S. Securities and Exchange Commission's suit names Immunosyn CEO Stephen Ferrone and Chief Financial Officer Douglas McClain Jr. as defendants and seeks disgorgement, civil penalties and an order blocking them from serving as an officer or director of a publicly traded company.

"From 2006...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Securities And Exchange Commission v. Ferrone et al


Case Number

1:11-cv-05223

Court

Illinois Northern

Nature of Suit

850(Securities/Commodities)

Judge

Honorable Jeffrey T. Gilbert

Date Filed

August 1, 2011

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.